Emera's investment thesis hinges on its ability to grow rate base and recover returns in a challenging regulatory environment. Revenue grew 15.3% YoY, but earned ROE of 8.2% remains below authorized levels, and EPS fell 24.4% in 2026Q2, indicating that aggress...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew 15.3% YoY, but operating margins are volatile (16.8% in 2026Q2 vs. 34.6% in 2025Q1), and EPS declined 24.4% YoY in 2026Q2, reflecting regulatory lag and cost pressures.
Emera has filed materials detailing a C$20 billion capital plan for 2026, which is expected to drive growth and enhance operational capabilities. This significant investment could position the company favorably in the energy sector.
The consensus rating for Emera among Wall Street analysts is 'Moderate Buy,' with a notable number of analysts recommending a buy. This positive sentiment reflects confidence in the company's future performance.
Overall, technical signals for Emera indicate a 'Strong Buy' candidate evaluation, with the stock trading above the Exponential Moving Average (EMA). This trend suggests bullish momentum and potential for continued price appreciation.
Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 7, 2026 | $0.49-2.2% vs $0.50 | $1.4B+5.4% vs $1.3B |
Q2 2026 May 8, 2026 | $0.98+13.7% vs $0.87 | $2.0B+16.1% vs $1.7B |
Q1 2026 Feb 23, 2026 | $0.40-3.9% vs $0.42 | $1.5B+28.5% vs $1.1B |
Q4 2025 Nov 7, 2025 | $0.63+3.4% vs $0.61 | $1.4B+7.9% vs $1.3B |
Shares of Emera Incorporated (TSE: EMA - Get Free Report) have earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target
Arcturus Therapeutics Holdings Inc. (the âCompanyâ, âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and
Engineers Gate Manager LP lifted its position in shares of eMagin Corporation (NYSE: EMA) by 182.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,564 shares of the company's stock after purchasing an additional 17,165 shares during the period.
[url="]Extreme Networks[/url], Inc. (NASDAQ: EXTR) today announced the general availability of [url="]Extreme Agent ONE⢠Coworker[/url], the next generation o
Benchmark EMA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Emera Incorporated (EMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $47.67 | $14.58B | 20.07 | 15.31% | 13.11% | 8.16% | 2.83% | |
| $14.92 | $10.64B | 11.84 | -0.37% | 14.62% | 17.1% | — | |
| $100.40 | $46.85B | 25.68 | 8.98% | 13.48% | 10.36% | — | |
| $32.76 | $24.65B | 20.60 | 6.85% | 13.47% | 8.53% | — | |
| $78.79 | $18.16B | 21.53 | 1.65% | 15.26% | 9.01% | — | |
| $94.62 | $11.47B | 18.74 | 4.2% | 11.52% | 8.99% | — |
Emera Incorporated (EMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Emera Incorporated (EMA) stock FAQ — growth, dividends, profitability & financials explained
Emera Incorporated (EMA) reported $8.58B in revenue for fiscal year 2025. This represents a 940% increase from $824.6M in 1999.
Emera Incorporated (EMA) grew revenue by 15.3% over the past year. This is strong growth.
Yes, Emera Incorporated (EMA) is profitable, generating $1.04B in net income for fiscal year 2025 (13.1% net margin).
Yes, Emera Incorporated (EMA) pays a dividend with a yield of 2.83%. This makes it attractive for income-focused investors.
Emera Incorporated (EMA) has a return on equity (ROE) of 8.2%. This is below average, suggesting room for improvement.
Emera Incorporated (EMA) had negative free cash flow of $1.12B in fiscal year 2025, likely due to heavy capital investments.
Emera Incorporated (EMA) has a dividend payout ratio of 53%. This suggests the dividend is well-covered and sustainable.
